KalVista Shares New Data on HAE Pill, Highlighting Early Treatment Results at ACAAI Conference
KalVista Shares New Data on HAE Pill, Highlighting Early Treatment Results at ACAAI Conference
KalVista公司在ACAAI會議上發佈HAE藥丸的新數據，突出早期治療結果
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024.
kalvista pharmaceuticals今天宣佈，在2024年10月24日至28日期間在美國波士頓舉行的美國變態反應哮喘和免疫學學院(ACAAI)上發佈了新的sebetralstat數據。
Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State Health, and KONFIDENT investigator, presented data on the Correlation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trial that showed complete attack resolution was achieved faster in attacks that were treated earlier (1st quartile) compared with those treated later (4th quartile).
tim董事，任教於賓夕法尼亞州立大學健康部門的內科和兒科肺部、變態反應和重症醫學系，並擔任KONFIDENt調查員，在sebetralstat KONFIDENt第3期試驗中就治療時間與發作持續時間的相關性進行了數據展示，結果顯示早期治療(第1四分位數)的發作在達到完全緩解方面比後期治療(第4四分位數)更快。
"This is the first time in a Phase...
「這是第一次在一...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間